Jeffreys Henry, the award-winning provider of audit, tax and advisory services to LSE, AIM and Aquis listed companies, has recently advised Poolbeg Pharma Plc, a pharmaceutical company, on its £50 million IPO on the AIM market of the London Stock Exchange.
Poolbeg Pharma, a spin out of Open Orphan, has successfully raised £25 million (before expenses) and lists with a market capitalisation of £50 million.
Poolbeg Pharma is a clinical-stage infectious disease pharmaceutical company. Their novel capital light clinical model enables them to develop multiple products faster and more cost effectively than the traditional biotech model.